首页> 外文期刊>Leukemia Research Reports >Unrelated HLA mismatched microtransplantation in a patient with refractory secondary acute myeloid leukemia
【24h】

Unrelated HLA mismatched microtransplantation in a patient with refractory secondary acute myeloid leukemia

机译:难治性继发性急性髓细胞白血病患者的不相关的HLA错配微移植

获取原文
           

摘要

Microtransplantation (MST), a type of HLA-mismatched allogeneic cellular therapy, is a promising, cellular therapy for acute myeloid leukemia (AML). MST transfuses granulocyte colony-stimulating factor (G-CSF)-mobilized, HLA-mismatched donor peripheral blood stem cells into patients undergoing conventional chemotherapy. MST, using haploidentical donors, has been shown to yield clinical benefit without any permanent marrow engraftment in AML. Consequently, graft-versus-host disease concerns are rendered irrelevant with no need for immunosuppression. We describe the first reported patient with refractory AML who underwent salvage MST from an unrelated, complete HLA-mismatched donor. The patient achieved remission without complication, warranting further study of unrelated HLA-mismatched donor MST in AML.
机译:微移植(MST)是一种HLA不匹配的同种异体细胞疗法,是一种有望用于急性髓细胞白血病(AML)的细胞疗法。 MST将粒细胞集落刺激因子(G-CSF)动员的,HLA不匹配的供体外周血干细胞输注到接受常规化疗的患者中。已经证明,使用单倍体供体的MST可以产生临床益处,而无需在AML中永久植入骨髓。因此,不需要免疫抑制就可以避免移植物抗宿主疾病。我们描述了第一例报告的难治性AML患者,他们从无关的,完整的HLA不匹配供体中接受MST抢救。该患者获得缓解而无并发症,因此有必要进一步研究AML中不相关的HLA不匹配供体MST。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号